免疫介导性炎症疾病患者的治疗策略 - Suppr

Suppr

超能文献

Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases.

作者信息

Curtis Jeffrey R, Ogdie Alexis, George Michael D

机构信息

University of Alabama at Birmingham.

University of Pennsylvania Medical Center, Philadelphia.

出版信息

JAMA. 2021 May 4;325(17):1726-1728. doi: 10.1001/jama.2021.2740.

DOI:10.1001/jama.2021.2740

PMID:33944889

Abstract

摘要

相似文献

Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases.

JAMA. 2021 May 4;325(17):1726-1728. doi: 10.1001/jama.2021.2740.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.

Aliment Pharmacol Ther. 2019 Mar;49(6):816-817. doi: 10.1111/apt.15081.

Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy - early promise but more data needed. Authors' reply.

Aliment Pharmacol Ther. 2019 Mar;49(6):817-818. doi: 10.1111/apt.15151.

Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.

J Crohns Colitis. 2019 Apr 26;13(5):539-540. doi: 10.1093/ecco-jcc/jjy202.

Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.

Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90-8. doi: 10.1016/j.clinre.2015.05.019. Epub 2015 Jun 29.

Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1638. doi: 10.1016/j.cgh.2017.05.017. Epub 2017 May 18.

Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.

Aliment Pharmacol Ther. 2018 Feb;47(3):448-449. doi: 10.1111/apt.14456.

Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.

Intern Med J. 2019 Apr;49(4):513-518. doi: 10.1111/imj.14064.

Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive.

Clin Gastroenterol Hepatol. 2018 Apr;16(4):597-598. doi: 10.1016/j.cgh.2017.11.033.

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1580-1588.e3. doi: 10.1016/j.cgh.2017.03.031. Epub 2017 Mar 30.

引用本文的文献

Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.

Ther Drug Monit. 2023 Oct 1;45(5):579-590. doi: 10.1097/FTD.0000000000001095. Epub 2023 Apr 3.

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control.

JAMA. 2023 Mar 28;329(12):1024-1026. doi: 10.1001/jama.2023.0492.

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.

BioDrugs. 2022 Nov;36(6):731-748. doi: 10.1007/s40259-022-00559-1. Epub 2022 Oct 31.

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.

J Intern Med. 2022 Sep;292(3):477-491. doi: 10.1111/joim.13495. Epub 2022 Apr 26.

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.

JAMA. 2021 Dec 21;326(23):2375-2384. doi: 10.1001/jama.2021.21316.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验